AUGUST 5, 2016 BY FINK DENSFORD   TransEnterix (NYSE:TRXC) hasn’t had the best luck in 2016, with the FDA denying its 510(k) clearance submission in April and shareholders suing the company in June over the nixed project, but things are looking up for the robotics company with the release of 2nd quarter earnings that beat the […]